...
首页> 外文期刊>Hematological oncology >Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry
【24h】

Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

机译:霍奇金淋巴瘤的治疗结果:巴西前瞻性注册处的第一个报告

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Data about Hodgkin lymphoma (HL) in developing countries are scarce and suggest the existence of substantial disparities in healthcare and outcomes in large areas of the world. In 2009, a prospective registry of HL was implemented in Brazil. Web‐based data were contributed by 20 institutions across the country participating in the Brazilian Prospective Hodgkin's Lymphoma Registry. The aim of this study was to present the clinical features and outcomes of newly diagnosed patients with HL aged 13 to 90?years. Multivariate Cox regression models were used to estimate progression‐free (PFS) and overall survival (OS) by clinical factors . A total of 674 patients with classical HL were analysed, with a median follow‐up of 37?months. Median age was 30?years (13‐90). The median time from the onset of symptoms to diagnosis was 6?months (0‐60). Only 6% of patients had early favourable disease, while 65% had advanced disease. Stage IVB was present in 26% and a high‐risk International Prognostic Score in 38%. Doxorubicin, bleomycin, vinblastine, and dacarbazine was used in 93%. The median dose of radiotherapy was 36?Gy for localized disease and 32?Gy for advanced disease. The 3?year PFS in early favourable, early unfavourable, and advanced disease were 95%, 88%, and 66%, respectively. High‐risk International Prognostic Score, advanced disease, and age greater than or equal to 60 were independently associated with poorer PFS and OS; performance status greater than or equal to 2 was also associated with a poorer OS. Poor‐risk patients predominated. Radiation doses for localized disease appear higher than current recommendations. Outcomes appear inferior in developing countries than in developed countries. Delayed diagnosis is probably a major factor underlying these findings. Scattered reports from developing nations suggest that many aspects of standard care in developed countries remain unmet needs for populations living in developing countries. The present report contributes to this body of data, with a proper description of what is currently achieved in urban areas in Brazil.
机译:摘要关于发展中国家霍奇金淋巴瘤(HL)的数据很少,表明世界上大部分地区在医疗保健和预后方面存在巨大差异。2009年,在巴西实施了HL的预期登记。网络数据由全国20家参与巴西霍奇金淋巴瘤登记的机构提供。本研究的目的是介绍新诊断的13-90岁HL患者的临床特征和结果?年。多变量Cox回归模型用于根据临床因素评估无进展(PFS)和总生存率(OS)。共分析了674例典型HL患者,中位随访时间为37?月。中位年龄是30岁?年(13-90岁)。从症状出现到确诊的中位时间为6?月数(0-60)。只有6%的患者有早期有利疾病,而65%的患者有晚期疾病。IVB期出现率为26%,高风险国际预后评分为38%。93%的患者使用阿霉素、博莱霉素、长春花碱和达卡巴嗪。放射治疗的中位剂量是36?Gy代表局限性疾病,32?Gy用于晚期疾病。3号?早期有利、早期不利和晚期疾病的年PFS分别为95%、88%和66%。高危国际预后评分、晚期疾病和年龄大于或等于60岁与PFS和OS较差独立相关;性能状态大于或等于2也与较差的操作系统有关。以低风险患者为主。局部疾病的辐射剂量似乎高于目前的建议。发展中国家的结果似乎不如发达国家。延迟诊断可能是这些发现背后的一个主要因素。来自发展中国家的零星报告表明,发达国家标准护理的许多方面仍然没有满足发展中国家人口的需求。本报告提供了大量数据,并对巴西城市地区目前取得的成就进行了适当描述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号